前列腺素D2作为过敏喘的调解者
T Matsuoka1, M Hirata, H Tanaka
1Department of Pharmacology, Kyoto University Faculty of Medicine, Kyoto 606-8501, Japan.
概括
前列腺素D2 (PGD2) 通过激活巨细胞,在过敏性喘中起着关键作用. 缺乏PGD2受体 (DP) 的小鼠显示喘症状减少,表明PGD2对于触发过敏气道炎症至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏研究 研究过敏
- 呼吸系统医学 呼吸系统医学
背景情况:
- 过敏性喘涉及T助手2型 (TH2) 细胞因子产生细胞,乙素透和支气管过敏反应.
- 乳腺细胞被免疫球蛋白E (IgE) 激活,在过敏反应期间释放诸如前列腺素D2 (PGD2) 等介质.
研究的目的:
- 调查前列腺素D2 (PGD2) 在过敏性喘中的作用.
- 确定PGD2通过其受体 (DP) 发送信号是否对喘发育至关重要.
主要方法:
- 产生缺少PGD2受体的小鼠 (DP-/-小鼠).
- 在DP-/-和野生型小鼠中使用卵胺 (OVA) 敏感化和气溶挑战诱导过敏喘.
- 评估血清IgE水平,TH2细胞因子度,淋巴细胞积累,乙素透和呼吸道过敏反应.
主要成果:
- 在OVA挑战后,DP-/-小鼠表现出与野生类型小鼠相似的IgE增加.
- 被OVA挑战的DP-/-小鼠显示TH2细胞因子水平显著降低,肺部的淋巴细胞积累.
- 与对照组相比,DP-/-小鼠表现出极少的乙氨基透和缺乏气道过度反应.
结论:
- 前列腺素D2 (PGD2) 在触发过敏喘反应时起到关键的杆细胞衍生媒介的作用.
- 通过其受体 (DP) 抑制PGD2信号传递可以改善关键的喘病理,包括炎症和过度反应.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...


